SCHEMBL18270971

SCHEMBL18270971

Cc1ccc2c(c1)CN([C@H]1CCCC(=O)NC1=O)C2=O

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 11/20 0.63
CSNK1A1 P48729 3/20 0.57
IKZF2 Q9UKS7 10/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5958854 0.93 CRBN (0.73) CRBNCSNK1A1IKZF2
SCHEMBL22703743 0.93 CRBN (0.73) CRBNCSNK1A1IKZF2
SCHEMBL22703752 0.93 CRBN (0.73) CRBNCSNK1A1IKZF2
SCHEMBL30930592 0.85 CRBN (0.63) CRBNCSNK1A1IKZF2
SCHEMBL18270982 0.85 CRBN (0.86) CRBNCSNK1A1IKZF2
SCHEMBL22639152 0.85 CRBN (0.86) CRBNCSNK1A1IKZF2
SCHEMBL26021396 0.83 CRBN (0.57) CRBNCSNK1A1IKZF2
SCHEMBL19451224 0.82 CRBN (0.73) CRBNCSNK1A1
SCHEMBL22703748 0.82 CRBN (0.73) CRBNCSNK1A1
SCHEMBL22703755 0.82 CRBN (0.73) CRBNCSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298004-B1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX INC (US) 2021-01-06 EP disclosed
US-10669260-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-06-02 US disclosed
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-02-18 US disclosed
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2019-09-12 US disclosed
US-9938302-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-04-10 US disclosed
US-20180065952-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2018-03-08 US disclosed
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
WO-2017201069-A1 OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS BIOTHERYX, INC. (US) 2017-11-23 WO disclosed
US-9822098-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2017-11-21 US disclosed
US-20160362397-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2016-12-15 US disclosed
WO-2016191178-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065952-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, APC CRBN 548/4885CSNK1A1 453/4885IKZF2 9/4885
US-10669260-B2 Compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, APC CRBN 548/4885CSNK1A1 453/4885IKZF2 9/4885
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B CRBN 176/4885CSNK1A1 9/4885IKZF2 44/4885
US-20160362397-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, APC CRBN 548/4885CSNK1A1 453/4885IKZF2 9/4885
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B CRBN 176/4885CSNK1A1 9/4885IKZF2 44/4885
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B CRBN 176/4885CSNK1A1 9/4885IKZF2 44/4885
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B CRBN 176/4885CSNK1A1 9/4885IKZF2 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.